In the subgroup analysis of the TRITON-TIMI 38 trial, prasugrel, another effective ADP P2Y12 antagonist, reduced the risk of cardiovascular death, myocardial infarction, or stroke by 4.8% compared with clopidogrel (30% relative) [8]. Here, P2RY12 is linked to Stroke.